|
Title
|
|
|
|
Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Increased expression of glucose transporters has been reported in many cancers. It is not known whether Sodium dependent GLucose Transporter 1 (SGLT1) is up-regulated in pancreatic cancer. We studied the expression of SGLT1, Bcl-2 and p53 in primary pancreatic adenocarcinomas related to survival. In primary tumors, mean SGLT1-Hscore (n = 83) was 4.24 (median 3.0, range 0.515.0). Patients with positive staining for Bcl-2 had higher mean SGLT1-Hscores than those without Bcl-2 expression: 5.87 vs. 3.07 (P = 0.025). No correlation was found between expression of p53 and SGLT1 (P = 0.881). On multivariate analysis TNM stage (P = 0.015) and SGLT1 (P = 0.030) showed prognostic value for disease free survival (DFS). For overall survival (OS), TNM stage (P<0.001) and chemotherapy (P = 0.048) were prognostic and SGLT1 showed a trend (P = 0.071). In a subgroup of younger patients (age ⩽ median, 63.9 y) who did not receive chemotherapy, SGLT1 was a very strong predictor of DFS (P = 0.005). We conclude that high SGLT1 expression (H score > median, 3.0) in pancreatic adenocarcinomas was significantly correlated with DFS and a trend was found for OS, especially in younger patients. High SGLT1 expression in primary tumors was correlated with high Bcl-2 expression, not with p53 expression. This supports our hypothesis that SGLT1 and Bcl-2 expression could serve as prognostic markers in pancreatic cancer. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Cancer investigation. - New York, N.Y.
Cancer investigation. - New York, N.Y.
| |
|
Publication
|
|
|
|
New York, N.Y.
:
2008
| |
|
ISSN
|
|
|
|
0735-7907
| |
|
Volume/pages
|
|
|
|
26
:8
(2008)
, p. 852-859
| |
|
ISI
|
|
|
|
000259993600012
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|